Attention Deficit Hyperactivity Disorder (ADHD) Market Report

Attention Deficit Hyperactivity Disorder (ADHD) Market Analysis Report By Drug Type (Stimulant, Non-stimulant), By Demographic, By Distribution Channel (Hospital & Retail Pharmacy), And Segment Forecasts, 2019 - 2025

  • Published Date: Feb, 2019
  • Base Year for Estimate: 2018
  • Report ID: GVR-2-68038-795-7
  • Format: Electronic (PDF)
  • Historical Data: 2014 - 2018
  • Number of Pages: 100

Industry Insights

The global attention deficit hyperactivity disorder market size was valued at USD 16.4 billion in 2018 and is estimated to exhibit a CAGR of 6.4% over the forecast period. Product launches across the globe, approval of new drugs, and increased research and development activities are likely to drive the market.

Increase in awareness about mental health among the general population and governments is expected to propel the ADHD market. Rising number of people suffering from a host of mental health disorders, including attention-deficit/hyperactivity disorder, has caught the attention of governments around the world, forcing them to take necessary steps to address this condition. In 2016, the U.S. Department of Health & Human Services awarded up to USD 54 million to the Substance Abuse and Mental Health Services Administration (SAMHSA) for the next four years to address the needs of individuals with serious mental illnesses.

U.S. attention deficit hyperactivity disorder market

Similarly, NHS England set up a five-year plan for mental health in 2016. The government committed to implementing this plan by 2020–2021, investing USD 1.27 billion into the project. Therefore, government support, along with growing awareness among various parties, is anticipated to boost the market.

Approval and commercialization of new drugs by market players is also expected to play a crucial role in driving market growth over the coming years. For instance, in August 2017, Shire launched FDA-approved MYDAYIS for the treatment of ADHD patients of the age 13 and older.

Drug Type Insights

By type of drug, the market has been segmented into stimulant and non-stimulant drugs. Stimulant drugs include Amphetamine, Methylphenidate, Lisdexamfetamine, Dexmethylphenidate. Non-stimulant drugs include Atomoxetine, Guanfacine, Clonidine, and Bupropion.

The stimulant segment accounted for the largest share in the ADHD market in 2018 and is expected to maintain its dominance throughout the forecast period. This can be attributed to high demand for these drugs due to their effectiveness in treating symptoms of attention-deficit/hyperactivity disorder, ongoing clinical trials, and government support for the use of stimulants in the treatment of mental health disorders. In April 2016, Tris Pharma, Inc. announced the launch of its FDA-approved liquid ADHD medication Dyanavel XR (amphetamine), which is used to treat patients over the age of six.

Non-stimulants are expected to exhibit the fastest growth rate during the forecast period due to their long-lasting effect compared to stimulants. The fact that these drugs present no risk of substance abuse is also a key factor boosting segment growth. Furthermore, an increasing number of market players have been investing in the development of non-stimulant drugs for attention-deficit/hyperactivity disorder, which is driving the segment.

Demographic Insights

On the basis of demographics, the attention-deficit/hyperactivity disorder (ADHD) market has been bifurcated into children (2-17 years of age) and adults (aged 18 and above). The adult segment held the largest share in the market in 2018 and this can be attributed to a large patient population. According to ADD Health and Wellness Centers, Inc., attention-deficit/hyperactivity disorder affects more than 4.0% of the adult population in U.S. According to the U.S. Substance Abuse and Mental Health Services Administration (SAMHSA), in 2015, there were 17.2 million individuals who used stimulants, of which 1.8 million were youth (age 12-17) and 4.9 million were adults (age 18-25).

Distribution Channel Insights

Based on distribution channel of ADHD drugs, the market has been segmented into hospital and retail pharmacies. In 2018, retail pharmacy accounted for the maximum market share. Increasing number of prescriptions and rise in patient care initiatives by retail pharmacies have driven the segment. 

Global ADHD market

ADHD inpatients are fewer in number compared to patients in homecare settings owing to the lengthy nature of the treatment of the condition. Patients prefer purchasing drugs from retail pharmacies rather than hospitals and therefore, the segment is expected to retain its lead throughout the forecast period. The segment is also anticipated to register the highest CAGR of 6.6% from 2019 to 2025.

Regional Insights

North America dominated the global market and accounted for more than 68.0% of the total market in 2018. This can be attributed to the large volume of drug prescriptions every year, increasing product launches, and rise in collaboration among players to enhance market penetration and for product development.

In August 2017, Shire launched a new prescription drug MYDAYIS (latest formulation of Adderall) in U.S. for ADHD patients over the age of 13. In October 2018, Dr. Reddy’s Laboratories launched Atomoxetine capsule to treat attention-deficit/hyperactivity disorder in U.S. Hence, commercialization of products is expected to boost the North America market.

Europe is expected to grow at the fastest rate during the forecast period due to increasing awareness about mental health, rising prevalence of attention-deficit/hyperactivity disorder, high consumption of additives and preservatives, and improving coverage for treatment of the condition.

ADHD Market Share Insights

Key players in the market include Eli Lily & Company; Pfizer; Johnson & Johnson Services, LLC; Lupin; Shire; Mallinckrodt; Prude Pharma L.P.; and NEOS Therapeutics Inc. Development of effective and economical products and geographical expansion are some of the major strategies adopted by market players to remain competitive.

For instance, in December 2015, Pfizer received the U.S. FDA approval of Quillichew ER, a chewable tablet for treatment of ADHD in patients 6 years and above. This is available in 20mg, 30mg, and 40mg formulations. Furthermore, in February 2018 Lupin launched a generic version of Kapvay in U.S, which expanded its product line for the treatment of attention-deficit/hyperactivity disorder.

Report Scope

Attribute

Details

Base year for estimation

2018

Actual estimates/Historical data

2014 - 2018

Forecast period

2019 - 2025

Market representation

Revenue in USD Million & CAGR from 2019 to 2025

Regional scope

North America, Europe, Asia Pacific, Latin America,& MEA

Country scope

U.S., Canada, U.K., Germany, France, Japan, China, Brazil, Mexico, & South Africa

Report coverage

Revenue forecast, company share, competitive landscape, growth factors & trends

15% free customization scope (equivalent to 5 analyst working days)

If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of customization


Segments Covered in the Report

This report forecasts revenue growth on global, regional, and country levels and provides an analysis on latest industry trends in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the global attention deficit hyperactivity disorder (ADHD) market report based on drug type, demographic, distribution channel, and region:

  • Drug Outlook (Revenue, USD Million, 2014 - 2025)

    • Amphetamine

    • Methylphenidate

    • Lisdexamfetamine

    • Dexmethylphenidate

    • Atomoxetine

    • Guanfacine

    • Clonidine

    • Bupropion

  • Drug Type Outlook (Revenue, USD Million, 2014 - 2025)

    • Stimulant

    • Non-stimulant

  • Demographic Outlook (Revenue, USD Million, 2014 - 2025)

    • Adult (Aged 18 and above)

    • Children

  • Distribution Channel Outlook (Revenue, USD Million, 2014 - 2025)

    • Retail Pharmacy

    • Hospital Pharmacy

  • Regional Outlook (Revenue, USD Million, 2014 - 2025)

    • North America

      • U.S.

      • Canada

    • Europe

      • UK

      • Germany

      • France

    • Asia Pacific

      • China

      • Japan

    • Latin America

      • Brazil

      • Mexico

    • MEA

      • South Africa

Key questions answered by the report
Request for Customization

Choose License Type

Single User - $5,950
Multi User (2-5) - $6,950
Enterprise Access - $8,950

Buy Chapters or Sections

Avail customized purchase options to meet your exact research needs:

  • Buy sections of this report
  • Buy country level reports
  • Request for historical data
  • Request discounts available for Start-Ups & Universities

Why Choose Us

  • Research support

    24/5 Research support

    Get your queries resolved from an industry expert.

  • Custom research service

    Custom research service

    Design an exclusive study to serve your research needs.

  • Quality assurance

    Quality assurance

    A testimonial for service in the form of BBB "A" Accreditation.

  • BBB Rating dandb
  • Information security

    Information security

    Your personal and confidential information is safe and secure.

  • grand view research PCI DSS complaint grand view research paypal verified